NCT06776081 is a NA clinical trial of Weight loss without pharmacotherapy in Obesity, sponsored by University of Colorado, Boulder.

Who is sponsoring NCT06776081?

NCT06776081 is sponsored by University of Colorado, Boulder.

What drugs are being tested in NCT06776081?

Interventions in NCT06776081: Weight loss without pharmacotherapy.

What condition does NCT06776081 study?

NCT06776081 studies Obesity, Weight Loss.

Is NCT06776081 still recruiting?

NCT06776081 is currently recruiting now. Last updated 15 January 2025.

Last reviewed 2025-01-15 · How we verify

NCT06776081

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function

Recruiting now NA Last updated 15 January 2025

What this trial tests

NA trial testing Weight loss without pharmacotherapy in Obesity in 84 participants. Currently enrolling.

Timeline

1 July 2024

Primary endpoint
30 June 2027

30 June 2027

Quick facts

Lead sponsor	University of Colorado, Boulder
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	84
Start date	1 July 2024
Primary completion	30 June 2027
Estimated completion	30 June 2027
Sites	1 location across United States

Drugs / interventions tested

Weight loss without pharmacotherapy — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →
Weight Loss — all drugs for Weight Loss →

Sponsor

University of Colorado, Boulder

Who can join

40 and older, any sex, with Obesity or Weight Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose tissue health and systemic messengers, regulators and mediators of cardiometabolic health and disease with obesity. The investigators hypothesize that elevated Ad-EVs in adults with obesity will be negatively associated with endothelium-dependent vasodilation. Furthermore, the investigators hypothesize that in adults with obesity, intentional weight loss-induced reduction in circulating Ad-EVs is associated with greater endothelium-dependent vasodilation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mesenchymal stem cell-derived extracellular vesicles for disease therapy by regulating ferroptosis: focus on diabetes mellitus and diabetic complications.
Wu J, Zhou Z, Qian H. · · 2025 · PMID 41382238 · DOI 10.1186/s13287-025-04852-y

Verify or expand the search:

Other trials of Weight loss without pharmacotherapy

Trials testing the same drug.

NCT06913712 — BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment · recruiting
NCT07455630 — Cardiac Function and Biomarkers in Patients With Obesity and Overweight · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other University of Colorado, Boulder trials

Trials by the same sponsor.

NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use · Phase 2, PHASE3 · not yet recruiting
NCT07011160 — Neural Substrates Underlying Adaptations in Manual Dexterity of Older Adults · NA · not yet recruiting
NCT07127965 — Exercise Adherence and Cognitive Decline: Phase 2 · NA · recruiting
NCT06588582 — Perceptual Influences From Smoking Cannabis: an Experimental Study · NA · recruiting
NCT06769022 — Exercise Adherence and Cognitive Decline · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06776081 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Boulder
Last refreshed: 15 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06776081.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing